Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage

Datamonitor
September 29, 2008
SKU: DFMN1926007
License type:
Table of Contents Related Reports
Introduction

The antidyslipidemic market is expected to fall to $20 billion in 2017. The decline will be driven by the deep genericization of the market, further exacerbated by the patent expiries of the top antidyslipidemic, Pfizer's Lipitor, as well as by the recent negative messages from the ILLUMINATE and ENHANCE clinical trials.

Reasons to Purchase
  • Quantify the future size and understand the background of the antidyslipidemic market
  • Understand the commercial landscape in terms of new product potential
  • Understand the barriers to uptake for novel antidyslipidemics.


Please Note: This product is delivered as a zip file


 

Share this report


Other tasks

 
 

Research Assistance

Ask a question
 

Related Markets


Cardiovascular Reports

 
 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!